Celldex Therapeutics Closes $345M Public Stock Offering

Biotech firm raises funds to advance pipeline of immune-based therapies.

Apr. 7, 2026 at 6:09am

Got story updates? Submit your updates here. ›

An extreme close-up of heavy, industrial-looking gears and mechanical components in shades of steel gray, bronze, and black, conceptually representing the complex financial infrastructure and machinery behind a major biotech capital raise.Celldex's $345 million public stock offering provides critical capital to advance its pipeline of innovative immune-based therapies.Boston Today

Celldex Therapeutics, a clinical-stage biotech company focused on mast cell biology and immune-based therapeutics, has closed a $345 million public stock offering. The offering included the full exercise of the underwriters' option to purchase additional shares, resulting in the sale of nearly 12 million shares at $29 per share. Celldex plans to use the proceeds to advance its pipeline of antibody-based treatments for severe inflammatory, allergic, and autoimmune diseases.

Why it matters

This capital raise will provide Celldex with significant resources to accelerate the development of its innovative pipeline of immune-modulating therapies, which have the potential to transform the treatment of a range of debilitating conditions. As a clinical-stage biotech, Celldex's ability to fund late-stage trials and prepare for potential commercialization is crucial to delivering new treatment options to patients.

The details

The public offering included the sale of 11,896,750 shares of Celldex's common stock, including the full exercise of the underwriters' option to purchase an additional 1,551,750 shares. All shares were sold by Celldex at a price of $29 per share, resulting in gross proceeds of approximately $345 million before underwriting discounts, commissions, and other offering-related expenses.

  • Celldex announced the closing of the public offering on April 6, 2026.
  • The company's shelf registration statement was previously filed with the SEC and became effective on November 3, 2023.

The players

Celldex Therapeutics, Inc.

A clinical-stage biotechnology company leading the science at the intersection of mast cell biology and the development of transformative therapeutics for patients with severe inflammatory, allergic, autoimmune and other devastating diseases.

Leerink Partners

One of the joint bookrunning managers for Celldex's public offering.

TD Cowen

One of the joint bookrunning managers for Celldex's public offering.

Guggenheim Securities

One of the joint bookrunning managers for Celldex's public offering.

Cantor

One of the joint bookrunning managers for Celldex's public offering.

Got photos? Submit your photos here. ›

What they’re saying

“This capital raise will provide Celldex with significant resources to accelerate the development of its innovative pipeline of immune-modulating therapies, which have the potential to transform the treatment of a range of debilitating conditions.”

— Sarah Cavanaugh, Senior Vice President, Corporate Affairs & Administration

What’s next

Celldex plans to use the proceeds from the public offering to advance its pipeline of antibody-based treatments for severe inflammatory, allergic, and autoimmune diseases.

The takeaway

Celldex's successful $345 million public stock offering demonstrates investor confidence in the company's innovative approach to immune-based therapies and positions it to accelerate the development of potentially transformative treatments for patients with a range of debilitating conditions.